Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Peng, Cike [VerfasserIn]   i
 Wallwiener, Markus [VerfasserIn]   i
 Cuk, Katarina [VerfasserIn]   i
 Modugno, Caroline [VerfasserIn]   i
 Heil, Jörg [VerfasserIn]   i
 Marmé, Frederik [VerfasserIn]   i
 Madhavan, Dharanija [VerfasserIn]   i
 Nees, Juliane [VerfasserIn]   i
 Schott, Sarah [VerfasserIn]   i
 Sohn, Christof [VerfasserIn]   i
 Schneeweiss, Andreas [VerfasserIn]   i
 Yang, Rongxi [VerfasserIn]   i
 Burwinkel, Barbara [VerfasserIn]   i
Titel:Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer
Verf.angabe:Cike Peng, Markus Wallwiener, Anja Rudolph, Katarina Ćuk, Ursula Eilber, Muhabbet Celik, Caroline Modugno, Andreas Trumpp, Jörg Heil, Frederik Marmé, Dharanija Madhavan, Juliane Nees, Sabine Riethdorf, Sarah Schott, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, Jenny Chang‐Claude, Rongxi Yang and Barbara Burwinkel
Jahr:2016
Jahr des Originals:2015
Umfang:11 S.
Fussnoten:Online 19 December 2015 ; Gesehen am 11.09.2019
Titel Quelle:Enthalten in: International journal of cancer
Ort Quelle:Bognor Regis : Wiley-Liss, 1966
Jahr Quelle:2016
Band/Heft Quelle:138(2016), 10, Seite 2499-2509
ISSN Quelle:1097-0215
Abstract:Conventional tumor markers have limited value for prognostication and treatment monitoring in metastatic breast cancer (MBC) patients and novel circulating tumor markers therefore need to be explored. Hyaluronic acid (HA) is a major macropolysaccharide in the extracellular matrix and is reported to be associated with tumor progression. In our study, we investigated plasma HA level with respect to progression free survival (PFS) and overall survival (OS), as well as the treatment monitoring value in MBC patients. The prognostic value of plasma HA level was investigated in a discovery cohort of 212 MBC patients with 2.5-year follow-up and validated in an independent validation cohort of 334 patients with 5-year follow-up. The treatment monitoring value of plasma HA level was investigated in 61 MBC patients from discovery cohort who had been radiographically examined after first complete cycle of chemo therapy. We found a robust association between high plasma HA level and poor prognosis of MBC patients in both discovery (pPFS = 7.92 × 10−6 and pOS = 5.27 × 10−5) and validation studies (pPFS = 3.66 × 10−4 and pOS = 1.43 × 10−4). In the discovery cohort, the plasma HA level displayed independent prognostic value after adjusted for age and clinicopathological factors, with respect to PFS and OS. Further, the decrease of plasma HA level displayed good concordance with treatment response evaluated by radiographic examination (AUC = 0.79). Plasma HA level displays prognostic value, as well as treatment monitoring value for MBC patients.
DOI:doi:10.1002/ijc.29975
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1002/ijc.29975
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.29975
 DOI: https://doi.org/10.1002/ijc.29975
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:biomarker
 hyaluronic acid
 metastatic breast cancer
 plasma
 prognosis
K10plus-PPN:1676500898
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68429059   QR-Code
zum Seitenanfang